IDLDX: IDL Diagnostics AB (publ) - Summary | Jitta

IDL Diagnostics AB (publ)

SWE:IDLDX

Price
kr0.47
Loss Chance
54.1%
2.37JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
32 / 107
288 / 616
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (49)
Recent Business Performance (54)
Financial Strength (45)
Return to Shareholders (0)
Competitive Advantage (29)
Jitta Signs
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 264.02% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.37
100.00%
2.89
152.39%
Life Sciences Tools and Services
5.71
226.12%
1.91
100.00%
5.41
149.38%
COMPANY DESCRIPTION
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.